Argitalpenak (25) PATRICIA DIEZHANDINO GARCIA argitalpenak

2024

  1. Long Term Follow-Up Observation in Small Choroidal Melanocytic Tumors

    Cancers, Vol. 16, Núm. 15

  2. Status of head and neck brachytherapy in Spain in 2022

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 456-460

2023

  1. A study comparing baseline and best-corrected visual acuity after iodine-125 episcleral brachytherapy in uveal melanoma

    Journal of Contemporary Brachytherapy, Vol. 15, Núm. 5, pp. 350-356

  2. Brachytherapy in the prevention of recurrence of conjunctival melanoma: Results of a case report in a University Hospital in Valladolid, Spain

    Strahlentherapie und Onkologie, Vol. 199, Núm. 11, pp. 1025-1030

2021

  1. Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height

    Journal of Contemporary Brachytherapy, Vol. 13, Núm. 2, pp. 117-125

2020

  1. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR)

    Clinical and Translational Oncology, Vol. 22, Núm. 8, pp. 1378-1389

2019

  1. Treatment planning considerations for 125I eye plaque brachytherapy

    Journal of Contemporary Brachytherapy, Vol. 11, Núm. 3, pp. 280-284

2018

  1. Metástasis intraoculares: comparación entre las formas de presentación clínica con tumor primario conocido y desconocido

    Archivos de la Sociedad Española de Oftalmologia, Vol. 93, Núm. 1, pp. 7-14

  2. Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: Part I

    Journal of Contemporary Brachytherapy, Vol. 10, Núm. 4, pp. 337-346

  3. Radiobiological doses, tumor, and treatment features influence on outcomes after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: Part II

    Journal of Contemporary Brachytherapy, Vol. 10, Núm. 4, pp. 347-359

  4. Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses

    Journal of Contemporary Brachytherapy, Vol. 10, Núm. 2, pp. 123-131

2017

  1. Pattern of Local Recurrence After I-125 Episcleral Brachytherapy for Uveal Melanoma in a Spanish Referral Ocular Oncology Unit

    American Journal of Ophthalmology, Vol. 180, pp. 39-45

2016

  1. 5-Fluorouracil, 5-Fluracil, Fluorouracil, Fu

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 479-486

  2. Capecitabina. Xeloda®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 77-84

  3. Denosumab, Prolia®, Xgeva®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 131-138

  4. Linfoma folicular primario de la conjuntiva simulando conjuntivitis crónica

    Archivos de la Sociedad Española de Oftalmologia, Vol. 91, Núm. 2, pp. 86-89

  5. Zoledronic Acid, Zometa®, Aclasta®, Reclast®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 469-477

2013

  1. Tumor pigmentado del cuerpo ciliar: ¿benigno o maligno?

    Archivos de la Sociedad Española de Oftalmologia, Vol. 88, Núm. 12, pp. 485-488

2010

  1. Parkinsonism secondary to metastatic lesions within the central nervous system: A case report

    Journal of Medical Case Reports, Vol. 4

2004

  1. Diseño, análisis y presentación de estudios: Sembrar para luego recoger

    Medicina Paliativa, Vol. 11, Núm. 1, pp. 35-42